CA2880174A1 - Composition for agent for external use - Google Patents
Composition for agent for external use Download PDFInfo
- Publication number
- CA2880174A1 CA2880174A1 CA2880174A CA2880174A CA2880174A1 CA 2880174 A1 CA2880174 A1 CA 2880174A1 CA 2880174 A CA2880174 A CA 2880174A CA 2880174 A CA2880174 A CA 2880174A CA 2880174 A1 CA2880174 A1 CA 2880174A1
- Authority
- CA
- Canada
- Prior art keywords
- agent
- composition
- external use
- use according
- minoxidil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 79
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 74
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 57
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 claims abstract description 35
- 229960003632 minoxidil Drugs 0.000 claims abstract description 35
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract description 23
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims abstract description 23
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract description 23
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 21
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 21
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 21
- 229960003943 hypromellose Drugs 0.000 claims abstract description 21
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 16
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 150000005846 sugar alcohols Polymers 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 9
- 229940058015 1,3-butylene glycol Drugs 0.000 claims description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 8
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 8
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 7
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- 235000015165 citric acid Nutrition 0.000 claims description 3
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 3
- 229940113120 dipropylene glycol Drugs 0.000 claims description 3
- 239000000174 gluconic acid Substances 0.000 claims description 3
- 235000012208 gluconic acid Nutrition 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 229960005150 glycerol Drugs 0.000 claims description 3
- 235000011167 hydrochloric acid Nutrition 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 229960003511 macrogol Drugs 0.000 claims description 3
- 235000011007 phosphoric acid Nutrition 0.000 claims description 3
- 229960004063 propylene glycol Drugs 0.000 claims description 3
- 235000013772 propylene glycol Nutrition 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 21
- 239000002562 thickening agent Substances 0.000 abstract description 12
- 239000013049 sediment Substances 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 4
- 238000013461 design Methods 0.000 abstract description 2
- XLYOFNOQVPJJNP-DYCDLGHISA-N deuterium hydrogen oxide Chemical compound [2H]O XLYOFNOQVPJJNP-DYCDLGHISA-N 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 31
- 235000019441 ethanol Nutrition 0.000 description 18
- 238000012360 testing method Methods 0.000 description 15
- 238000011156 evaluation Methods 0.000 description 13
- 239000008213 purified water Substances 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- -1 etc.) Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 229920003117 medium viscosity grade hydroxypropyl cellulose Polymers 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 241000173529 Aconitum napellus Species 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 241000726094 Aristolochia Species 0.000 description 1
- 235000008658 Artemisia capillaris Nutrition 0.000 description 1
- 241000092668 Artemisia capillaris Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 235000004237 Crocus Nutrition 0.000 description 1
- 241000596148 Crocus Species 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 244000061508 Eriobotrya japonica Species 0.000 description 1
- 235000009008 Eriobotrya japonica Nutrition 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241001289529 Fallopia multiflora Species 0.000 description 1
- 244000111489 Gardenia augusta Species 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 244000141009 Hypericum perforatum Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- 235000014435 Mentha Nutrition 0.000 description 1
- 241001072983 Mentha Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- NWBJYWHLCVSVIJ-UHFFFAOYSA-N N-benzyladenine Chemical compound N=1C=NC=2NC=NC=2C=1NCC1=CC=CC=C1 NWBJYWHLCVSVIJ-UHFFFAOYSA-N 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 241000168720 Panax japonicus Species 0.000 description 1
- 235000003174 Panax japonicus Nutrition 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 241000133134 Saussurea Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241001530209 Swertia Species 0.000 description 1
- 240000002299 Symphytum officinale Species 0.000 description 1
- 235000005865 Symphytum officinale Nutrition 0.000 description 1
- 244000162450 Taxus cuspidata Species 0.000 description 1
- 235000009065 Taxus cuspidata Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229940023019 aconite Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- BBFQZRXNYIEMAW-UHFFFAOYSA-N aristolochic acid I Chemical compound C1=C([N+]([O-])=O)C2=C(C(O)=O)C=C3OCOC3=C2C2=C1C(OC)=CC=C2 BBFQZRXNYIEMAW-UHFFFAOYSA-N 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- RZMKWKZIJJNSLQ-UHFFFAOYSA-M carpronium chloride Chemical compound [Cl-].COC(=O)CCC[N+](C)(C)C RZMKWKZIJJNSLQ-UHFFFAOYSA-M 0.000 description 1
- 229950003631 carpronium chloride Drugs 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229960002350 guaiazulen Drugs 0.000 description 1
- 229920003112 high viscosity grade hydroxypropyl cellulose Polymers 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 229960003517 isothipendyl Drugs 0.000 description 1
- OQJBSDFFQWMKBQ-UHFFFAOYSA-N isothipendyl Chemical compound C1=CN=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 OQJBSDFFQWMKBQ-UHFFFAOYSA-N 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003534 oscillatory effect Effects 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 1
- 229940081510 piroctone olamine Drugs 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- TXGSOSAONMOPDL-UHFFFAOYSA-N propan-2-yl 3,4,5-trihydroxybenzoate Chemical compound CC(C)OC(=O)C1=CC(O)=C(O)C(O)=C1 TXGSOSAONMOPDL-UHFFFAOYSA-N 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/24—Phosphorous; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/26—Optical properties
- A61K2800/262—Transparent; Translucent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/48—Thickener, Thickening system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/591—Mixtures of compounds not provided for by any of the codes A61K2800/592 - A61K2800/596
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Abstract
Upon attempting to design a pharmaceutical preparation by mixing minoxidil with a general thickening agent during a process for considering a minoxidil-containing composition for an agent for external use in which dripping is inhibited, it was discovered that the pharmaceutical preparation would have sediments or would cloud and that a sufficient viscosity of the pharmaceutical preparation could not be obtained. The minoxidil-containing composition for an agent for external use of the present invention is characterized by containing minoxidil (a), a hydroxypropyl cellulose and hypromellose (b), ethanol (c), and water (d). Said composition is clear and has a good feel upon use, and dripping of the composition is inhibited.
Description
DESCRIPTION
COMPOSITION FOR AGENT FOR EXTERNAL USE
Technical Field [0001]
The present invention relates a composition for agent for external use containing minoxidil as an active ingredient, and also relates to a minoxidil-containing composition for agent for external use, which is clear and viscous, is inhibited from dripping, and has a good comfort of use.
Background Art [0002]
The chemical name of minoxidil is 6-(1-piperidiny1)-2,4-pyrimidinediamine-3-oxide, and the application of minoxidil as a hair restorer has been known (see Patent Literature 1).
When externally applied, minoxidil has excellent hair-fostering and hair-growing effects. Thus, hair restorers containing minoxidil have been widely accepted. Currently, minoxidil-containing pharmaceutical preparations in lotion form are commercially available.
In the case of pharmaceutical preparations in lotion form, it is concerned that dripping may occur during use. Accordingly, there has been a demand for a dripless minoxidil-containing composition for agent for external use. However, in the actual situation, a minoxidil product with sufficiently inhibited dripping has not yet been provided.
Incidentally, "dripping"
herein means that in the case where a composition for agent for external use is applied to an affected part such as the scalp, the pharmaceutical solution runs off the application part, causing the deterioration of the comfort of use.
COMPOSITION FOR AGENT FOR EXTERNAL USE
Technical Field [0001]
The present invention relates a composition for agent for external use containing minoxidil as an active ingredient, and also relates to a minoxidil-containing composition for agent for external use, which is clear and viscous, is inhibited from dripping, and has a good comfort of use.
Background Art [0002]
The chemical name of minoxidil is 6-(1-piperidiny1)-2,4-pyrimidinediamine-3-oxide, and the application of minoxidil as a hair restorer has been known (see Patent Literature 1).
When externally applied, minoxidil has excellent hair-fostering and hair-growing effects. Thus, hair restorers containing minoxidil have been widely accepted. Currently, minoxidil-containing pharmaceutical preparations in lotion form are commercially available.
In the case of pharmaceutical preparations in lotion form, it is concerned that dripping may occur during use. Accordingly, there has been a demand for a dripless minoxidil-containing composition for agent for external use. However, in the actual situation, a minoxidil product with sufficiently inhibited dripping has not yet been provided.
Incidentally, "dripping"
herein means that in the case where a composition for agent for external use is applied to an affected part such as the scalp, the pharmaceutical solution runs off the application part, causing the deterioration of the comfort of use.
[0003]
Generally, in order to provide a composition for agent for external use that is inhibited from dripping, it is possible to use a thickening agent.
Citation List Patent Literature [0004]
Patent Literature 1: US 4139619 Summary of Invention Technical Problem [0005]
Upon attempting to design a pharmaceutical preparation by mixing minoxidil with a general thickening agent during a process for considering a minoxidil-containing composition for agent for external use that is inhibited from dripping, the present inventors have discovered that such a pharmaceutical preparation would have sediments or would cloud and that a sufficient viscosity of the pharmaceutical preparation could not be obtained.
Generally, in order to provide a composition for agent for external use that is inhibited from dripping, it is possible to use a thickening agent.
Citation List Patent Literature [0004]
Patent Literature 1: US 4139619 Summary of Invention Technical Problem [0005]
Upon attempting to design a pharmaceutical preparation by mixing minoxidil with a general thickening agent during a process for considering a minoxidil-containing composition for agent for external use that is inhibited from dripping, the present inventors have discovered that such a pharmaceutical preparation would have sediments or would cloud and that a sufficient viscosity of the pharmaceutical preparation could not be obtained.
[0006]
An object of the invention is to provide a minoxidil-containing composition for agent for external use that is inhibited from dripping, and also to provide a composition for agent for external use, which is a clear pharmaceutical preparation having a good comfort of use.
Solution to Problem [0007]
The present inventors have conducted extensive research to solve the above problems.
As a result, they have found that a composition for agent for external use containing minoxidil, hydroxypropyl cellulose, hypromellose, ethanol, and water is clear and viscous, is free from dripping, has moderate adhesion at an affected part, and has a good comfort of use. The present invention has thus been accomplished based on this finding.
That is, the present invention provides:
(1) A composition for agent for external use, comprising:
(a) minoxidil, (b) hydroxypropyl cellulose and hypromellose, (c) ethanol, and (d) water;
(2) The composition for agent for external use according to (1), having a hydroxypropyl cellulose content of 0.05 to 2.5 wiv%;
(3) The composition for agent for external use according to (1) or (2), having a hydroxypropyl cellulose content of 0.1 to 2 w/v%;
(4) The composition for agent for external use according to any one of (1) to (3), having a viscosity of 30 to 250 mPa.s at 25 C;
(5) The composition for agent for external use according to any one of (1) to (4), further comprising an acid;
(6) The composition for agent for external use according to any one of (1) to (5), wherein the acid is at least one acid selected from the group consisting of citric acid, hydrochloric acid, lactic acid, phosphoric acid, tartaric acid, and gluconic acid;
(7) The composition for agent for external use according to any one of (1) to (6), having a pH of 5.0 to 8.5;
An object of the invention is to provide a minoxidil-containing composition for agent for external use that is inhibited from dripping, and also to provide a composition for agent for external use, which is a clear pharmaceutical preparation having a good comfort of use.
Solution to Problem [0007]
The present inventors have conducted extensive research to solve the above problems.
As a result, they have found that a composition for agent for external use containing minoxidil, hydroxypropyl cellulose, hypromellose, ethanol, and water is clear and viscous, is free from dripping, has moderate adhesion at an affected part, and has a good comfort of use. The present invention has thus been accomplished based on this finding.
That is, the present invention provides:
(1) A composition for agent for external use, comprising:
(a) minoxidil, (b) hydroxypropyl cellulose and hypromellose, (c) ethanol, and (d) water;
(2) The composition for agent for external use according to (1), having a hydroxypropyl cellulose content of 0.05 to 2.5 wiv%;
(3) The composition for agent for external use according to (1) or (2), having a hydroxypropyl cellulose content of 0.1 to 2 w/v%;
(4) The composition for agent for external use according to any one of (1) to (3), having a viscosity of 30 to 250 mPa.s at 25 C;
(5) The composition for agent for external use according to any one of (1) to (4), further comprising an acid;
(6) The composition for agent for external use according to any one of (1) to (5), wherein the acid is at least one acid selected from the group consisting of citric acid, hydrochloric acid, lactic acid, phosphoric acid, tartaric acid, and gluconic acid;
(7) The composition for agent for external use according to any one of (1) to (6), having a pH of 5.0 to 8.5;
(8) The composition for agent for external use according to any one of (1) to (7), having a pH of 5.5 to 7.0;
(9) The composition for agent for external use according to any one of (1) to (8), having an ethanol content of 25 to 70 w/v%;
(10) The composition for agent for external use according to any one of (1) to (9), having an ethanol content of 50 to 70 w/v%;
(11) The composition for agent for external use according to any one of (1) to (10), having a minoxidil content of 1 to 10 w/v%;
(12) The composition for agent for external use according to any one of (1) to (11), further comprising a polyalcohol;
(13) The composition for agent for external use according to (12), wherein the polyalcohol is at least one member selected from the group consisting of 1,3-butylene glycol, propylene glycol, glycerin, dipropylene glycol, Macrogol 400, and Macrogol 600;
(14) The composition for agent for external use according to (12), wherein the polyalcohol is 1,3-butylene glycol; and (15) The composition for agent for external use according to (1) to (14), having a dosage form of gel, lotion, or liquid.
Advantageous Effects of Invention [0008]
The present invention enables the provision of a minoxidil-containing composition for agent for external use, which is clear and viscous, is inhibited from dripping, and has a good comfort of use.
Description of Embodiments [0009]
The present invention will be described in detail hereinafter.
As the minoxidil to be used in the present invention, general pharmaceutical quality ones can be suitably used. The amount of minoxidil incorporated ranges 1 to 10 w/v%, preferably 3 to 8 w/v%, and more preferably 5 to 8 w/v% in the composition for agent for external use.
[0010]
In the composition for agent for external use of the present invention, hydroxypropyl cellulose and hypromellose are incorporated as thickening agents.
With respect to the hydroxypropyl cellulose, it is preferable for it to have a viscosity of its 2 w/v% aqueous solution at 20 C (measured according to The Japanese Pharmacopoeia, 14th Edition, The Second Method (rotational viscometer)) of more than 150 mPa.s and 4,000 mPa-s or less. As the hydroxypropyl cellulose to be used, general pharmaceutical quality ones can be suitably used. The hydroxypropyl cellulose may be a commercially available product. For example, it is possible to use NISSO HPC-H (Nippon Soda Co., Ltd.), NISSO HPC-M (Nippon Soda Co., Ltd.), etc. In addition, the amount of hydroxypropyl cellulose incorporated ranges preferably 0.05 to 2.5 w/v%, and more preferably 0.1 to 2 w/v%, in the composition for agent for external use of the present invention.
[0011]
With respect to the hypromellose, it is preferable for it to have an viscosity of its 2 w/v% aqueous solution at 20 C (measured according to The Japanese Pharmacopoeia, 14th Edition, The Second Method (rotational viscometer)) of more than 7,500 mPa.s and 14,000 mPa.s or less. As the hypromellose to be used, general pharmaceutical quality ones can be suitably used. The hypromellose may be a commercially available product. For example, it is possible to use METOLOSE 60SH-10000 (Shin-Etsu Chemical Co., Ltd.), etc. In addition, the amount of hypromellose incorporated ranges preferably 0.01 to 1 w/v%, and more preferably 0.01 to 0.5 w/v%, in the composition for agent for external use of the present invention.
[0012]
It is preferable that the viscosity of the composition for agent for external use of the present invention ranges 30 to 250 mPa.s at 25 C. The composition for agent for external use having a viscosity within the above range can be obtained by suitably selecting the kind and amount of hydroxypropyl cellulose and hypromellose to be used mainly.
Therefore, the ratio between the contents of hydroxypropyl cellulose and hypromellose is not particularly limited.
In addition, it is necessary that the composition for agent for external use of the present invention contains both hydroxypropyl cellulose and hypromellose. For example, even if a viscosity of 30 InPa-s or more is achieved by hydroxypropyl cellulose alone without using hypromellose, dripping cannot necessarily be ameliorated. Incidentally, the viscosity of the composition for agent for external use of the present invention is measured using an oscillatory viscometer. In this application, the viscosity at 25 C is determined using VISCOMATE VM-100A
(Yamaichi Electronics, Inc.), and the conditions, such as the probe to be used, are selected according to its operation manual.
[0013]
The composition for agent for external use of the present invention contains hydroxypropyl cellulose and hypromellose as thickening agents. Attributable to this, it is now possible to produce a clear, minoxidil-containing composition for agent for external use with a good comfort of use, which is inhibited from dripping, and, moreover, is free from causing undesirable stickiness or caking when applied.
[0014]
In the composition for agent for external use of the present invention, an acid can be used to adjust the pH. Examples of acids include citric acid, hydrochloric acid, lactic acid, phosphoric acid, tartaric acid, and gluconic acid. For each, pharmaceutical quality products can be suitably used. In addition, the pH of the composition for agent for external use of the present invention ranges preferably 5 to 8.5, and more preferably 5.5 to 7.
[0015]
The amount of ethanol incorporated in the present invention ranges preferably 25 to 70 w/v% in the composition for agent for external use. When ethanol is incorporated into a composition for agent for external use in a large amount, thickening agents that can be incorporated while keeping the clearness of the composition are limited.
Therefore, it would be an outstanding advantage of the minoxidil-containing composition for agent for external use of the present invention that the present invention may be implemented with an amount of ethanol incorporated being within the range of 50 w/v% or more.
Advantageous Effects of Invention [0008]
The present invention enables the provision of a minoxidil-containing composition for agent for external use, which is clear and viscous, is inhibited from dripping, and has a good comfort of use.
Description of Embodiments [0009]
The present invention will be described in detail hereinafter.
As the minoxidil to be used in the present invention, general pharmaceutical quality ones can be suitably used. The amount of minoxidil incorporated ranges 1 to 10 w/v%, preferably 3 to 8 w/v%, and more preferably 5 to 8 w/v% in the composition for agent for external use.
[0010]
In the composition for agent for external use of the present invention, hydroxypropyl cellulose and hypromellose are incorporated as thickening agents.
With respect to the hydroxypropyl cellulose, it is preferable for it to have a viscosity of its 2 w/v% aqueous solution at 20 C (measured according to The Japanese Pharmacopoeia, 14th Edition, The Second Method (rotational viscometer)) of more than 150 mPa.s and 4,000 mPa-s or less. As the hydroxypropyl cellulose to be used, general pharmaceutical quality ones can be suitably used. The hydroxypropyl cellulose may be a commercially available product. For example, it is possible to use NISSO HPC-H (Nippon Soda Co., Ltd.), NISSO HPC-M (Nippon Soda Co., Ltd.), etc. In addition, the amount of hydroxypropyl cellulose incorporated ranges preferably 0.05 to 2.5 w/v%, and more preferably 0.1 to 2 w/v%, in the composition for agent for external use of the present invention.
[0011]
With respect to the hypromellose, it is preferable for it to have an viscosity of its 2 w/v% aqueous solution at 20 C (measured according to The Japanese Pharmacopoeia, 14th Edition, The Second Method (rotational viscometer)) of more than 7,500 mPa.s and 14,000 mPa.s or less. As the hypromellose to be used, general pharmaceutical quality ones can be suitably used. The hypromellose may be a commercially available product. For example, it is possible to use METOLOSE 60SH-10000 (Shin-Etsu Chemical Co., Ltd.), etc. In addition, the amount of hypromellose incorporated ranges preferably 0.01 to 1 w/v%, and more preferably 0.01 to 0.5 w/v%, in the composition for agent for external use of the present invention.
[0012]
It is preferable that the viscosity of the composition for agent for external use of the present invention ranges 30 to 250 mPa.s at 25 C. The composition for agent for external use having a viscosity within the above range can be obtained by suitably selecting the kind and amount of hydroxypropyl cellulose and hypromellose to be used mainly.
Therefore, the ratio between the contents of hydroxypropyl cellulose and hypromellose is not particularly limited.
In addition, it is necessary that the composition for agent for external use of the present invention contains both hydroxypropyl cellulose and hypromellose. For example, even if a viscosity of 30 InPa-s or more is achieved by hydroxypropyl cellulose alone without using hypromellose, dripping cannot necessarily be ameliorated. Incidentally, the viscosity of the composition for agent for external use of the present invention is measured using an oscillatory viscometer. In this application, the viscosity at 25 C is determined using VISCOMATE VM-100A
(Yamaichi Electronics, Inc.), and the conditions, such as the probe to be used, are selected according to its operation manual.
[0013]
The composition for agent for external use of the present invention contains hydroxypropyl cellulose and hypromellose as thickening agents. Attributable to this, it is now possible to produce a clear, minoxidil-containing composition for agent for external use with a good comfort of use, which is inhibited from dripping, and, moreover, is free from causing undesirable stickiness or caking when applied.
[0014]
In the composition for agent for external use of the present invention, an acid can be used to adjust the pH. Examples of acids include citric acid, hydrochloric acid, lactic acid, phosphoric acid, tartaric acid, and gluconic acid. For each, pharmaceutical quality products can be suitably used. In addition, the pH of the composition for agent for external use of the present invention ranges preferably 5 to 8.5, and more preferably 5.5 to 7.
[0015]
The amount of ethanol incorporated in the present invention ranges preferably 25 to 70 w/v% in the composition for agent for external use. When ethanol is incorporated into a composition for agent for external use in a large amount, thickening agents that can be incorporated while keeping the clearness of the composition are limited.
Therefore, it would be an outstanding advantage of the minoxidil-containing composition for agent for external use of the present invention that the present invention may be implemented with an amount of ethanol incorporated being within the range of 50 w/v% or more.
[0016]
The amount of water incorporated in the present invention ranges preferably 5 to 30 w/v% in the composition for agent for external use. As each of the ethanol and water to be used, general pharmaceutical quality ones can be suitably used.
The amount of water incorporated in the present invention ranges preferably 5 to 30 w/v% in the composition for agent for external use. As each of the ethanol and water to be used, general pharmaceutical quality ones can be suitably used.
[0017]
The composition for agent for external use of the present invention may contain a polyalcohol. Examples of usable polyalcohols include 1,3-butylene glycol, propylene glycol, glycerin, dipropylene glycol, Macrogol 400, and Macrogol 600. In particular, 1,3-butylene glycol is preferable. The amount of polyalcohol incorporated ranges preferably 1 to 30 w/v()/0 in the composition for agent for external use, and more preferably 5 to 20 w/v% in the composition for agent for external use. As the polyalcohol to be used, general pharmaceutical quality ones can be suitably used.
The composition for agent for external use of the present invention may contain a polyalcohol. Examples of usable polyalcohols include 1,3-butylene glycol, propylene glycol, glycerin, dipropylene glycol, Macrogol 400, and Macrogol 600. In particular, 1,3-butylene glycol is preferable. The amount of polyalcohol incorporated ranges preferably 1 to 30 w/v()/0 in the composition for agent for external use, and more preferably 5 to 20 w/v% in the composition for agent for external use. As the polyalcohol to be used, general pharmaceutical quality ones can be suitably used.
[0018]
The dosage form of the minoxidil-containing composition for agent for external use of the present invention is not particularly limited. The dosage form is preferably a gel, a lotion, or a liquid.
The dosage form of the minoxidil-containing composition for agent for external use of the present invention is not particularly limited. The dosage form is preferably a gel, a lotion, or a liquid.
[0019]
Further, components that can optionally be incorporated into the composition for agent for external use of the present invention include those which are selected from the group consisting of menthol, tocopherol acetate, pyridoxine hydrochloride, and pantothenyl ethyl ether (hereinafter referred to as "optional components"). The amount thereof incorporated is not particularly limited, and can be determined considering the comfort of use, the stability of minoxidil, etc. As each of the optional components to be used, general pharmaceutical quality ones can be suitably used.
Further, components that can optionally be incorporated into the composition for agent for external use of the present invention include those which are selected from the group consisting of menthol, tocopherol acetate, pyridoxine hydrochloride, and pantothenyl ethyl ether (hereinafter referred to as "optional components"). The amount thereof incorporated is not particularly limited, and can be determined considering the comfort of use, the stability of minoxidil, etc. As each of the optional components to be used, general pharmaceutical quality ones can be suitably used.
[0020]
In the composition for agent for external use of the present invention, in addition to the components mentioned above, various components generally used for agents for external use can be incorporated without interfering with the advantageous effects of the present invention.
Examples thereof include components that are generally used, such as excipients, hair-fostering components (6-benzyl aminopurine, adenosine, pentadecanoic acid glyceride, Polygonum multiflorum, Panax japonicus, etc.), vasodilators (carpronium chloride, benzyl nicotinate, swertia herb extract, Panax schinseng extract, capsicum tincture, etc.), antihistamines (diphenhydramine hydrochloride, isothipendyl hydrochloride, etc.), anti-inflammatory agents (guaiazulene, etc.), keratolytic drugs (urea, salicylic acid, etc.), disinfectants (chlorhexidine glyconate, isopropylmethylphenol, quaternary ammonium salts, piroctone olamine, etc.), moisturizers (hyaluronic acid or a salt thereof, chondroitin sulfate, etc.), extracts of various animals and plants (Taxus cuspidata, moutan bark, liquorice, St. John's wort, aconite, loquat, Artemisia capillaris, comfrey, angelica, crocus, gardenia fruit, rosemary, sage, Saussurea root, Aristolochia root, hop, placenta, etc.), vitamins (retinol acetate, ascorbic acid, thiamine nitrate, cyanocobalamine, biotin, etc.), antioxidants (dibutylhydroxytoluene, sodium pyrosulfite, tocopherol, sodium edetate, ascorbic acid, isopropyl gallate, etc.), solubilizers (diisopropyl adipate, isopropyl myristate, various vegetable oils, various animal oils, hydrocarbons, etc.), metabolism activators (panthenol, etc.), adhesives, perfumes, refreshing agents (mentha oil, camphor, etc.), and dyes.
In the composition for agent for external use of the present invention, in addition to the components mentioned above, various components generally used for agents for external use can be incorporated without interfering with the advantageous effects of the present invention.
Examples thereof include components that are generally used, such as excipients, hair-fostering components (6-benzyl aminopurine, adenosine, pentadecanoic acid glyceride, Polygonum multiflorum, Panax japonicus, etc.), vasodilators (carpronium chloride, benzyl nicotinate, swertia herb extract, Panax schinseng extract, capsicum tincture, etc.), antihistamines (diphenhydramine hydrochloride, isothipendyl hydrochloride, etc.), anti-inflammatory agents (guaiazulene, etc.), keratolytic drugs (urea, salicylic acid, etc.), disinfectants (chlorhexidine glyconate, isopropylmethylphenol, quaternary ammonium salts, piroctone olamine, etc.), moisturizers (hyaluronic acid or a salt thereof, chondroitin sulfate, etc.), extracts of various animals and plants (Taxus cuspidata, moutan bark, liquorice, St. John's wort, aconite, loquat, Artemisia capillaris, comfrey, angelica, crocus, gardenia fruit, rosemary, sage, Saussurea root, Aristolochia root, hop, placenta, etc.), vitamins (retinol acetate, ascorbic acid, thiamine nitrate, cyanocobalamine, biotin, etc.), antioxidants (dibutylhydroxytoluene, sodium pyrosulfite, tocopherol, sodium edetate, ascorbic acid, isopropyl gallate, etc.), solubilizers (diisopropyl adipate, isopropyl myristate, various vegetable oils, various animal oils, hydrocarbons, etc.), metabolism activators (panthenol, etc.), adhesives, perfumes, refreshing agents (mentha oil, camphor, etc.), and dyes.
[0021]
For the preparation of the composition for agent for external use of the present invention, for example, hydroxypropyl cellulose or hypromellose is swollen using purified water or ethanol, then minoxidil is added thereto, and further the above components are incorporated therein to prepare the composition. When the obtained composition for agent for external use has low viscosity, it can be provided as a liquid or a lotion. In the case of high viscosity, it is provided as a gel.
The composition for agent for external use of the present invention thus obtained can be used as an agent for hair, a pharmaceutical preparation for skin application, etc.
For the preparation of the composition for agent for external use of the present invention, for example, hydroxypropyl cellulose or hypromellose is swollen using purified water or ethanol, then minoxidil is added thereto, and further the above components are incorporated therein to prepare the composition. When the obtained composition for agent for external use has low viscosity, it can be provided as a liquid or a lotion. In the case of high viscosity, it is provided as a gel.
The composition for agent for external use of the present invention thus obtained can be used as an agent for hair, a pharmaceutical preparation for skin application, etc.
[0022]
Hereinafter, test examples, examples, and comparative examples will be given to describe the present invention in further detail. However, the present invention is not limited to these examples, etc.
Hereinafter, test examples, examples, and comparative examples will be given to describe the present invention in further detail. However, the present invention is not limited to these examples, etc.
[0023]
Test Example 1 (Influence of the Variation of Thickening Agent) According to the formulation shown in Table 1 below, the components were weighed.
Each of the thickening agents was dispersed and swollen in water, ethanol or 1,3-butylene glycol, then dibutylhydroxytoluene, minoxidil and phosphoric acid were added thereto, and the rest of the ethanol and purified water were further added thereto to make the total volume of 100mL, to provide pharmaceutical preparations of Reference Examples 1 to 11, respectively.
The external appearance of the provided pharmaceutical preparations was visually observed and evaluated according to the following criteria. The results are shown in Table 2.
[Criteria]
External Appearance o: The formation of sediments, clouding, or separation was not seen.
x: The formation of sediments, clouding, or separation was seen.
Test Example 1 (Influence of the Variation of Thickening Agent) According to the formulation shown in Table 1 below, the components were weighed.
Each of the thickening agents was dispersed and swollen in water, ethanol or 1,3-butylene glycol, then dibutylhydroxytoluene, minoxidil and phosphoric acid were added thereto, and the rest of the ethanol and purified water were further added thereto to make the total volume of 100mL, to provide pharmaceutical preparations of Reference Examples 1 to 11, respectively.
The external appearance of the provided pharmaceutical preparations was visually observed and evaluated according to the following criteria. The results are shown in Table 2.
[Criteria]
External Appearance o: The formation of sediments, clouding, or separation was not seen.
x: The formation of sediments, clouding, or separation was seen.
[0024]
[Table 1]
Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference Example 1 Example 2 Example 3 Example 4 Example 5 Example 6 Example 7 Exampde 8 Example 9 Example 10 Example 11 Minoxidil 5g 5g 5g 5g 5g 5g 5g 6g Egg 5g 5g Phosphoric acid O.
847g O. 847g 0 847g O. 847g 0, 847g O. 847g O. 847g O. 847g O. 847g O. 847g O.
847g Hydroxypropyl oskilose 1. 2g Hypromellose lg Carboxyinyl polymer lg Xanthan gum 3g Thidoing Hydroxyethyl celkdose agent Polyvinyl aloohol (parlialy saponified) ig Methyl virild ether-rnaleic anhydride copolymer 1 g Carrnellose sodium lg Pectin 1 g EthiA cefkilose 100 O. 2g POlyvinyl pyrrolidone K90 ig Dibutyihydroxytoluene O.
05g O. 05g O. 05g O. 05g O. 05g 0. 05g O. 05g O. 05g O. 05g O. 05g O. 05g 1,3-Butyiene glycol 10g 10g 10g 10g 10g 10g 10g 10g 10g 10g 10g Ethanol (95) 60g 60g 60g 60g 60g 60g 60g 60g 60g 60g 60g Purified water t3mLiit 1COmL in lag 100ntri fad 1rrLn1 100mL 100ntntotal103m1 ntrial 180 rnL h total 103 rtiikti100mLitial Snit:aged [0025]
[Table 2]
Extemal Appearance Reference Example 1 0 Reference Example 2 0 Comparative Example 3 Comparative Example 4 Comparative Example 5 Comparative Example 6 Comparative Example 7 Reference Example 8 Reference Example 9 Reference Example 10 0 Reference Example 11 0 [0026]
The above results show that the pharmaceutical preparations of Reference Examples 1, 2, 10, and 11 using hydroxypropyl cellulose, hypromellose, ethyl cellulose, and polyvinyl pyrrolidone, respectively, were free from the formation of sediments or clouding. However, with respect to the pharmaceutical preparations of Reference Examples 3 to 9 using carboxyvinyl polymer, xanthan gum, hydroxyethyl cellulose, polyvinyl alcohol, methyl vinyl ether-maleic anhydride copolymer, carmellose sodium, or pectin, respectively, the formation of sediments, clouding, or the like occurred during preparation, and it was difficult to prepare a pharmaceutical preparation with a clear external appearance.
[Table 1]
Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference Reference Example 1 Example 2 Example 3 Example 4 Example 5 Example 6 Example 7 Exampde 8 Example 9 Example 10 Example 11 Minoxidil 5g 5g 5g 5g 5g 5g 5g 6g Egg 5g 5g Phosphoric acid O.
847g O. 847g 0 847g O. 847g 0, 847g O. 847g O. 847g O. 847g O. 847g O. 847g O.
847g Hydroxypropyl oskilose 1. 2g Hypromellose lg Carboxyinyl polymer lg Xanthan gum 3g Thidoing Hydroxyethyl celkdose agent Polyvinyl aloohol (parlialy saponified) ig Methyl virild ether-rnaleic anhydride copolymer 1 g Carrnellose sodium lg Pectin 1 g EthiA cefkilose 100 O. 2g POlyvinyl pyrrolidone K90 ig Dibutyihydroxytoluene O.
05g O. 05g O. 05g O. 05g O. 05g 0. 05g O. 05g O. 05g O. 05g O. 05g O. 05g 1,3-Butyiene glycol 10g 10g 10g 10g 10g 10g 10g 10g 10g 10g 10g Ethanol (95) 60g 60g 60g 60g 60g 60g 60g 60g 60g 60g 60g Purified water t3mLiit 1COmL in lag 100ntri fad 1rrLn1 100mL 100ntntotal103m1 ntrial 180 rnL h total 103 rtiikti100mLitial Snit:aged [0025]
[Table 2]
Extemal Appearance Reference Example 1 0 Reference Example 2 0 Comparative Example 3 Comparative Example 4 Comparative Example 5 Comparative Example 6 Comparative Example 7 Reference Example 8 Reference Example 9 Reference Example 10 0 Reference Example 11 0 [0026]
The above results show that the pharmaceutical preparations of Reference Examples 1, 2, 10, and 11 using hydroxypropyl cellulose, hypromellose, ethyl cellulose, and polyvinyl pyrrolidone, respectively, were free from the formation of sediments or clouding. However, with respect to the pharmaceutical preparations of Reference Examples 3 to 9 using carboxyvinyl polymer, xanthan gum, hydroxyethyl cellulose, polyvinyl alcohol, methyl vinyl ether-maleic anhydride copolymer, carmellose sodium, or pectin, respectively, the formation of sediments, clouding, or the like occurred during preparation, and it was difficult to prepare a pharmaceutical preparation with a clear external appearance.
[0027]
According to the formulation shown in Tables 3 and 4 below, the components were weighed. Each of the thickening agents were dispersed and swollen in water, ethanol, or a polyalcohol, then minoxidil and an acid were added thereto, and the rest of the ethanol and purified water were further added thereto to make the total amount of 100 mL, to provide pharmaceutical preparations of Examples 1 to 11 and Comparative Examples 1 to 10. The provided pharmaceutical preparations were each placed in a glass bottle.
According to the formulation shown in Tables 3 and 4 below, the components were weighed. Each of the thickening agents were dispersed and swollen in water, ethanol, or a polyalcohol, then minoxidil and an acid were added thereto, and the rest of the ethanol and purified water were further added thereto to make the total amount of 100 mL, to provide pharmaceutical preparations of Examples 1 to 11 and Comparative Examples 1 to 10. The provided pharmaceutical preparations were each placed in a glass bottle.
[0028]
[Table 3]
Example 1 Example 21_Example 3 Example 4 Example 5 Example 6 Example 71 Example 8 Example 9 Example 10 Example 111 Minoxidil 5¾ 5g 5g 5g 5g 5g 3g I 8g 5g 3g 5g 1 Phosphoric acid 0. 847g O. 847g O. 847g O.
847g O. 847g 0. 847g - - O. 847g 0. 339g O. 847g I
Citric acid - - - - - - 0.2g - - - -Lactic acid - - - - 2g - - i - ' I
Hydroxypropyl cellulose (HPC-M) O. 5g O. 8g O. lg 1. Og 2g 2g O. 8g O. 8g O. 8g 2g 0 8g !
Hypromellose (METOLOSE 60SH-10000) O. 5g O. 2¾ O. 5g O. 2g O. 01g O. 3g O. 2¾ O. 2g O. 2g O. 01g O. 2g 1 1,3-Butylene giycol 10g 10g lOg 1 Og 10g 10g 8g - 1 Og 7g 1 _ , i Propylene glycol - - 10g - - -Ethanol (95) 60g 60g , 60g 60g 60g 60g 60g 60g 50g 70g 60g Purified water 1180 mL in toia1100 a in trtali100 ml_ iitatal 100 mL intots1103 mL ii tctal 100 mL intcta1100 mL 0.1111100 mL h total 100 mL in tota1100 mL in toto1103 rri in totall pH i 6.13 6.13 6.12 6.15 6.16 6.13 647 5.93 5.82 6.47 5.86 Viscosity 160.4mPa = s 47.0mPa = s 130.8rnPa = s 58.7mPa = s 124mPa = s 1 214mPa = 3 40.5mPa = s 44.9mPa = s 49.1mPa = s 100m Pa = s 41.7m Pa = s I
[Table 3]
Example 1 Example 21_Example 3 Example 4 Example 5 Example 6 Example 71 Example 8 Example 9 Example 10 Example 111 Minoxidil 5¾ 5g 5g 5g 5g 5g 3g I 8g 5g 3g 5g 1 Phosphoric acid 0. 847g O. 847g O. 847g O.
847g O. 847g 0. 847g - - O. 847g 0. 339g O. 847g I
Citric acid - - - - - - 0.2g - - - -Lactic acid - - - - 2g - - i - ' I
Hydroxypropyl cellulose (HPC-M) O. 5g O. 8g O. lg 1. Og 2g 2g O. 8g O. 8g O. 8g 2g 0 8g !
Hypromellose (METOLOSE 60SH-10000) O. 5g O. 2¾ O. 5g O. 2g O. 01g O. 3g O. 2¾ O. 2g O. 2g O. 01g O. 2g 1 1,3-Butylene giycol 10g 10g lOg 1 Og 10g 10g 8g - 1 Og 7g 1 _ , i Propylene glycol - - 10g - - -Ethanol (95) 60g 60g , 60g 60g 60g 60g 60g 60g 50g 70g 60g Purified water 1180 mL in toia1100 a in trtali100 ml_ iitatal 100 mL intots1103 mL ii tctal 100 mL intcta1100 mL 0.1111100 mL h total 100 mL in tota1100 mL in toto1103 rri in totall pH i 6.13 6.13 6.12 6.15 6.16 6.13 647 5.93 5.82 6.47 5.86 Viscosity 160.4mPa = s 47.0mPa = s 130.8rnPa = s 58.7mPa = s 124mPa = s 1 214mPa = 3 40.5mPa = s 44.9mPa = s 49.1mPa = s 100m Pa = s 41.7m Pa = s I
[0029]
[Table 4]
'Comparative Comparative Comparative Comparative Comparative Comparative I
Comparative Corporative I Corparative Comparative Example 1 Eunple 2 Earn* 3 Example 4 Example 5 Example 6 l Example 7 Example 8 ' Example 9 . Exainple 10 Wad 5g 5g 5g 5g 5g 5g 5g 5 gg . 5 5g Phosphoric acid O. 847g O. 847g O. 847g O. 847g O. 847g O. 847g O. 847g O.
847g ! O. 847g 0 847g Hydraypropyl cellulose (HPC-M) o lg O. 5g lg 5g - - -- ' 0. 5g , O. 5g Hypromellose (METOLOSE 60SH-10000) - - - - O. 05g 0. 1g O. 5g 1g ' - -Ethyl cellulose 100 - - - - - - - - lg -Polyvinyl pyrdidone K90 - - - - - - - - - 1 g 1,3-Butylene glycol 10g 10g 10g 10g 1 Og 10g 1 Og 1 Og 10g 10g Ethanol (95) 60g 60g 60g 60g 60g 60g 60g 60g 60g 60g Purified water 100 mL hloWl100 mL ii total 100 mt:n told 100mL OM 00 mL
httal 100 A total 100 rrtn dal 10Ornt. ill:0003mi. hila1100 nil_ Octal f-pH a 13 6.13 6.14 6.20 6.08 I 6.11 1 6.11 6.07 ! 6.05 6.11 Viscosity 4.43mPa = s 14.6mPa = s 38.5mPa = s 600mPa = s 4.14mPa =s_15.47mPa = s I 28.7mPa = s 90.3mPa = s i 39.8mPa = s 30.9mPa = s [0030]
Test Example 2 (Dripping Test) An alcohol test paper was placed on a flat plate at an angle of 20 , and 1000, of each of the pharmaceutical preparations of Examples 1 to 6 and 11 and Comparative Examples 1 to 10 was discharged onto the alcohol test paper at an angle of 90 . Thirty (30) seconds later, the dripping distance on the alcohol test paper was measured and evaluated according to the following evaluation criteria.
[Evaluation Criteria]
o: The dripping distance after 30 seconds is 50 mm or less.
x: The dripping distance after 30 seconds is more than 50 mm.
[Table 4]
'Comparative Comparative Comparative Comparative Comparative Comparative I
Comparative Corporative I Corparative Comparative Example 1 Eunple 2 Earn* 3 Example 4 Example 5 Example 6 l Example 7 Example 8 ' Example 9 . Exainple 10 Wad 5g 5g 5g 5g 5g 5g 5g 5 gg . 5 5g Phosphoric acid O. 847g O. 847g O. 847g O. 847g O. 847g O. 847g O. 847g O.
847g ! O. 847g 0 847g Hydraypropyl cellulose (HPC-M) o lg O. 5g lg 5g - - -- ' 0. 5g , O. 5g Hypromellose (METOLOSE 60SH-10000) - - - - O. 05g 0. 1g O. 5g 1g ' - -Ethyl cellulose 100 - - - - - - - - lg -Polyvinyl pyrdidone K90 - - - - - - - - - 1 g 1,3-Butylene glycol 10g 10g 10g 10g 1 Og 10g 1 Og 1 Og 10g 10g Ethanol (95) 60g 60g 60g 60g 60g 60g 60g 60g 60g 60g Purified water 100 mL hloWl100 mL ii total 100 mt:n told 100mL OM 00 mL
httal 100 A total 100 rrtn dal 10Ornt. ill:0003mi. hila1100 nil_ Octal f-pH a 13 6.13 6.14 6.20 6.08 I 6.11 1 6.11 6.07 ! 6.05 6.11 Viscosity 4.43mPa = s 14.6mPa = s 38.5mPa = s 600mPa = s 4.14mPa =s_15.47mPa = s I 28.7mPa = s 90.3mPa = s i 39.8mPa = s 30.9mPa = s [0030]
Test Example 2 (Dripping Test) An alcohol test paper was placed on a flat plate at an angle of 20 , and 1000, of each of the pharmaceutical preparations of Examples 1 to 6 and 11 and Comparative Examples 1 to 10 was discharged onto the alcohol test paper at an angle of 90 . Thirty (30) seconds later, the dripping distance on the alcohol test paper was measured and evaluated according to the following evaluation criteria.
[Evaluation Criteria]
o: The dripping distance after 30 seconds is 50 mm or less.
x: The dripping distance after 30 seconds is more than 50 mm.
[0031]
Test Example 3 (Comfort of Use Test) The comfort of use of the pharmaceutical preparations was evaluated by three special panelists. A sensory evaluation test was performed by the following scoring method: the pharmaceutical preparations of Examples 1 to 6 and 11 and Comparative Examples 1 to 10 were applied to the inside of the upper arm of three special panelists, and each panelist evaluated the preparations for "stickiness", "caking", and "spread". Incidentally, "caking"
herein refers to the phenomenon of appearing of the composition for agent for external use as a white powdery mass at or after the application of the composition to the scalp. As the evaluation method, five ratings from 1 to 5 were set for each evaluation item, and the panelists gave any one of 1 to 5.
Evaluation was made according to the following evaluation criteria.
[Evaluation Items]
1) Stickiness No stickiness is felt: Score 5 Slight stickiness is felt: Score 4 Stickiness is felt: Score 3 Slightly strong stickiness is felt: Score 2 Full stickiness is felt: Score 1 2) Caking No caking: Score 5 Caking occurred (slight caking): Score 4 Caking occurred (some caking): Score 3 Caking occurred (slightly significant caking): Score 2 Caking occurred (significant caking): Score 1 3) Spread Easy to spread (very easy): Score 5 Easy to spread (easy): Score 4 Easy to spread (slightly easy): Score 3 Hard to spread (slightly hard): Score 2 Hard to spread (very hard): Score 1 [Evaluation Criteria]
o: The average of the scores for each evaluation item is 3.5 or more.
x: The average of the scores for each evaluation item is less than 3.5.
Table 5 shows the results of the dripping test and the comfort of use test on Examples 1 to 6 and 11 and Comparative Examples 1 to 10, as well as their overall evaluation.
Test Example 3 (Comfort of Use Test) The comfort of use of the pharmaceutical preparations was evaluated by three special panelists. A sensory evaluation test was performed by the following scoring method: the pharmaceutical preparations of Examples 1 to 6 and 11 and Comparative Examples 1 to 10 were applied to the inside of the upper arm of three special panelists, and each panelist evaluated the preparations for "stickiness", "caking", and "spread". Incidentally, "caking"
herein refers to the phenomenon of appearing of the composition for agent for external use as a white powdery mass at or after the application of the composition to the scalp. As the evaluation method, five ratings from 1 to 5 were set for each evaluation item, and the panelists gave any one of 1 to 5.
Evaluation was made according to the following evaluation criteria.
[Evaluation Items]
1) Stickiness No stickiness is felt: Score 5 Slight stickiness is felt: Score 4 Stickiness is felt: Score 3 Slightly strong stickiness is felt: Score 2 Full stickiness is felt: Score 1 2) Caking No caking: Score 5 Caking occurred (slight caking): Score 4 Caking occurred (some caking): Score 3 Caking occurred (slightly significant caking): Score 2 Caking occurred (significant caking): Score 1 3) Spread Easy to spread (very easy): Score 5 Easy to spread (easy): Score 4 Easy to spread (slightly easy): Score 3 Hard to spread (slightly hard): Score 2 Hard to spread (very hard): Score 1 [Evaluation Criteria]
o: The average of the scores for each evaluation item is 3.5 or more.
x: The average of the scores for each evaluation item is less than 3.5.
Table 5 shows the results of the dripping test and the comfort of use test on Examples 1 to 6 and 11 and Comparative Examples 1 to 10, as well as their overall evaluation.
[0032]
[Table 5]
1 Comfort-of-use test Overall Dripping test Stickiness Caking Spread evaluation Example 1 0 0 0 0 0 Example 2 0 0 0 0 0 .
Example 3 0 0 0 0 0 Example 4 0 0 0 i 0 0 Example 5 0 0 0 0 0 Example 6 0 0 1 0 0 0 Example 11 0 0 0 0 0 Comparative Example 1 1 x 0 0 1 0 x Comparative Example 2 x 0 0 0 x Comparative Example 3 x 0 0 0 x Comparative Example 4 0 x x x x Comparative Example 5 x 0 0 0 x Comparative Example 6 x 0 0 0 x Comparative Example 7 x 0 0 0 x Comparative Example 8 1 0 x ' x 0 x Comparative Example 9 1 x 0 0 1 0 x i Comparative Example 10 x 0 i 0 0 x [0033]
The results from Test Examples 2 and 3 showed that no minoxidil-containing composition for agent for external use that is satisfactory in terms of both the dripping and the comfort of use could be achieved by using hydroxypropyl cellulose or hypromellose each alone as a thickening agent; however, incorporating hydroxypropyl cellulose and hypromellose in combination could produce a pharmaceutical preparation that is prevented from dripping, is free from causing stickiness and caking, is easy to spread, and has a good comfort of use.
Moreover, it was shown that dripping was effectively inhibited in Examples 1 and 2 than Comparative Example 3 containing the same amount of thickening agent. Further, it was shown that dripping is effectively inhibited in Example 3, in spite of the fact that the viscosity is lower than Comparative Example 3. Furthermore, it was shown that the preparations in Examples 1 and 2 are superior in terms of the comfort of use evaluated by being free from stickiness and caking, than Comparative Example 8 containing the same amount of thickening agent.
Industrial Applicability [0034]
According to the present invention, a minoxidil-containing composition for agent for external use that is inhibited from dripping and has a good comfort of use can be provided
[Table 5]
1 Comfort-of-use test Overall Dripping test Stickiness Caking Spread evaluation Example 1 0 0 0 0 0 Example 2 0 0 0 0 0 .
Example 3 0 0 0 0 0 Example 4 0 0 0 i 0 0 Example 5 0 0 0 0 0 Example 6 0 0 1 0 0 0 Example 11 0 0 0 0 0 Comparative Example 1 1 x 0 0 1 0 x Comparative Example 2 x 0 0 0 x Comparative Example 3 x 0 0 0 x Comparative Example 4 0 x x x x Comparative Example 5 x 0 0 0 x Comparative Example 6 x 0 0 0 x Comparative Example 7 x 0 0 0 x Comparative Example 8 1 0 x ' x 0 x Comparative Example 9 1 x 0 0 1 0 x i Comparative Example 10 x 0 i 0 0 x [0033]
The results from Test Examples 2 and 3 showed that no minoxidil-containing composition for agent for external use that is satisfactory in terms of both the dripping and the comfort of use could be achieved by using hydroxypropyl cellulose or hypromellose each alone as a thickening agent; however, incorporating hydroxypropyl cellulose and hypromellose in combination could produce a pharmaceutical preparation that is prevented from dripping, is free from causing stickiness and caking, is easy to spread, and has a good comfort of use.
Moreover, it was shown that dripping was effectively inhibited in Examples 1 and 2 than Comparative Example 3 containing the same amount of thickening agent. Further, it was shown that dripping is effectively inhibited in Example 3, in spite of the fact that the viscosity is lower than Comparative Example 3. Furthermore, it was shown that the preparations in Examples 1 and 2 are superior in terms of the comfort of use evaluated by being free from stickiness and caking, than Comparative Example 8 containing the same amount of thickening agent.
Industrial Applicability [0034]
According to the present invention, a minoxidil-containing composition for agent for external use that is inhibited from dripping and has a good comfort of use can be provided
Claims (15)
1. A composition for agent for external use, comprising:
(a) minoxidil, (b) hydroxypropyl cellulose and hypromellose, (c) ethanol, and (d) water.
(a) minoxidil, (b) hydroxypropyl cellulose and hypromellose, (c) ethanol, and (d) water.
2. The composition for agent for external use according to claim 1, having a hydroxypropyl cellulose content of 0.05 to 2.5 w/v%.
3. The composition for agent for external use according to claim 1 or 2, having a hydroxypropyl cellulose content of 0.1 to 2 w/v%.
4. The composition for agent for external use according to any one of claims 1 to 3, having a viscosity of 30 to 250 mPa.s at 25°C.
5. The composition for agent for external use according to any one of claims 1 to 4, further comprising an acid.
6. The composition for agent for external use according to claim 5, wherein the acid is at least one acid selected from the group consisting of citric acid, hydrochloric acid, lactic acid, phosphoric acid, tartaric acid, and gluconic acid.
7. The composition for agent for external use according to any one of claims 1 to 6, having a pH of 5.0 to 8.5.
8. The composition for agent for external use according to any one of claims 1 to 7, having a pH of 5.5 to 7Ø
9. The composition for agent for external use according to any one of claims 1 to 8, having an ethanol content of 25 to 70 w/v%.
10. The composition for agent for external use according to any one of claims 1 to 9, having an ethanol content of 50 to 70 w/v%.
11. The composition for agent for external use according to any one of claims 1 to 10, having a minoxidil content of 1 to 10 w/v%.
12. The composition for agent for external use according to any one of claims 1 to 11, further comprising a polyalcohol.
13. The composition for external use according to claim 12, wherein the polyalcohol is at least one member selected from the group consisting of 1,3-butylene glycol, propylene glycol, glycerin, dipropylene glycol, Macrogol 400, and Macrogol 600.
14. The composition for agent for external use according to claim 12, wherein the polyalcohol is 1,3-butylene glycol.
15. The composition for agent for external use according to claim 1 to 14, having a dosage form of gel, lotion, or liquid.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012-166882 | 2012-07-27 | ||
| JP2012166882 | 2012-07-27 | ||
| PCT/JP2013/070144 WO2014017573A1 (en) | 2012-07-27 | 2013-07-25 | Composition for agent for external use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2880174A1 true CA2880174A1 (en) | 2014-01-30 |
Family
ID=49997382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2880174A Abandoned CA2880174A1 (en) | 2012-07-27 | 2013-07-25 | Composition for agent for external use |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20150196476A1 (en) |
| EP (1) | EP2883538A1 (en) |
| JP (1) | JP6252475B2 (en) |
| KR (1) | KR20150037867A (en) |
| CN (1) | CN104487048A (en) |
| CA (1) | CA2880174A1 (en) |
| HK (1) | HK1206976A1 (en) |
| IN (1) | IN2015DN00560A (en) |
| MX (1) | MX2015000997A (en) |
| PH (1) | PH12015500138A1 (en) |
| RU (1) | RU2015106686A (en) |
| SG (1) | SG11201500544SA (en) |
| TW (1) | TW201406376A (en) |
| WO (1) | WO2014017573A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9675537B2 (en) | 2014-06-30 | 2017-06-13 | Johnson & Johnson Consumer Inc. | Hair growth composition and method |
| US11185487B2 (en) * | 2015-12-28 | 2021-11-30 | Johnson & Johnson Consumer Inc. | Hair growth composition and method |
| WO2019035874A1 (en) * | 2017-08-15 | 2019-02-21 | Sanford L.P. | Glue slime activator and associated methods and kits |
| US10738175B2 (en) * | 2017-08-15 | 2020-08-11 | Sanford, L.P. | Glue slime activator and associated methods and kits |
| JP2020023467A (en) * | 2018-01-19 | 2020-02-13 | ロート製薬株式会社 | External preparation, method for improving liquid breaking properties, and agent for improving liquid breaking properties |
| JP7379094B2 (en) * | 2019-11-01 | 2023-11-14 | 富士化学工業株式会社 | External liquid |
| JP7361004B2 (en) | 2020-09-08 | 2023-10-13 | 信越化学工業株式会社 | Method for producing alcohol composition |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4139619A (en) * | 1976-05-24 | 1979-02-13 | The Upjohn Company | 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth |
| JP2733980B2 (en) * | 1988-08-26 | 1998-03-30 | 大正製薬株式会社 | Hair restoration composition |
| JPH0977640A (en) * | 1995-09-14 | 1997-03-25 | Lion Corp | Hair-producing/hair grawing agent |
| JPH1192378A (en) * | 1997-09-19 | 1999-04-06 | Taisho Pharmaceut Co Ltd | Hair tonic liquid for external use |
| ES2688273T3 (en) * | 1999-03-31 | 2018-10-31 | Janssen Pharmaceutica Nv | Pregelatinized starch in a controlled release formulation |
| JP5527787B2 (en) * | 2000-04-07 | 2014-06-25 | 大正製薬株式会社 | Hair growth composition |
| US7442369B1 (en) * | 2000-08-09 | 2008-10-28 | Mcneil Ab | Compositions of minoxidil |
| JP2002308737A (en) * | 2001-04-05 | 2002-10-23 | Taisho Pharmaceut Co Ltd | Hair growing composition |
| JP2005119996A (en) * | 2003-10-15 | 2005-05-12 | Sato Pharmaceutical Co Ltd | Hair-restoring agent |
| JP4688579B2 (en) * | 2005-06-08 | 2011-05-25 | 株式会社マンダム | Scalp composition |
-
2013
- 2013-07-25 SG SG11201500544SA patent/SG11201500544SA/en unknown
- 2013-07-25 MX MX2015000997A patent/MX2015000997A/en unknown
- 2013-07-25 IN IN560DEN2015 patent/IN2015DN00560A/en unknown
- 2013-07-25 EP EP13823181.6A patent/EP2883538A1/en not_active Withdrawn
- 2013-07-25 RU RU2015106686A patent/RU2015106686A/en not_active Application Discontinuation
- 2013-07-25 CN CN201380039897.2A patent/CN104487048A/en active Pending
- 2013-07-25 WO PCT/JP2013/070144 patent/WO2014017573A1/en active Application Filing
- 2013-07-25 CA CA2880174A patent/CA2880174A1/en not_active Abandoned
- 2013-07-25 KR KR20157001735A patent/KR20150037867A/en not_active Application Discontinuation
- 2013-07-25 US US14/417,415 patent/US20150196476A1/en not_active Abandoned
- 2013-07-25 JP JP2014526989A patent/JP6252475B2/en active Active
- 2013-07-26 TW TW102126902A patent/TW201406376A/en unknown
-
2015
- 2015-01-22 PH PH12015500138A patent/PH12015500138A1/en unknown
- 2015-08-06 HK HK15107553.7A patent/HK1206976A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2015000997A (en) | 2015-04-09 |
| KR20150037867A (en) | 2015-04-08 |
| JPWO2014017573A1 (en) | 2016-07-11 |
| WO2014017573A1 (en) | 2014-01-30 |
| IN2015DN00560A (en) | 2015-06-26 |
| TW201406376A (en) | 2014-02-16 |
| US20150196476A1 (en) | 2015-07-16 |
| EP2883538A1 (en) | 2015-06-17 |
| JP6252475B2 (en) | 2017-12-27 |
| CN104487048A (en) | 2015-04-01 |
| RU2015106686A (en) | 2016-09-20 |
| SG11201500544SA (en) | 2015-04-29 |
| HK1206976A1 (en) | 2016-01-22 |
| PH12015500138A1 (en) | 2015-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2880174A1 (en) | Composition for agent for external use | |
| KR20190133803A (en) | Hair restoration/growth stimulating agent | |
| JP2007137899A (en) | Medicinal solution | |
| JP2012025770A (en) | Hair growth stimulant composition | |
| JP2016020379A (en) | Photoaging inhibitor and inhibitor for skin thinning | |
| JPWO2017026405A1 (en) | Composition for external use | |
| KR101670865B1 (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing Sinomenine Hydrochloride | |
| KR102164151B1 (en) | Hair growth agent composition | |
| JP2006022091A (en) | Composition for growing hair | |
| TW202000193A (en) | External-use composition | |
| JP2009096765A (en) | Composition for hair | |
| JP2008056703A (en) | Composition for hair restoration | |
| JP5780690B2 (en) | Hair growth composition | |
| JP4381350B2 (en) | New hair growth composition | |
| JP2017186310A (en) | Aerosol agent | |
| KR101618349B1 (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing Dehydroandrographolide | |
| JP2020002131A (en) | Liquid oral composition | |
| JP2010018555A (en) | Minoxidil-containing liquid formulation | |
| JP2007191473A (en) | New hair-growing composition | |
| TW202019383A (en) | External-use composition | |
| JP2020002023A (en) | Liquid oral composition | |
| JP7379094B2 (en) | External liquid | |
| JP2009215323A (en) | New hair growing composition | |
| KR102000935B1 (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing 5-hydroxytryptophan | |
| KR101618350B1 (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing 5-hydroxytryptophan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20170725 |